A rapid and sensitive HPLC-MS method for the detection of plasma and cellular rifampicin

Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences

Volumn 857, Issue 1, 2007, Pages 76-82

  Hartkoorn, Ruben C ^a   Khoo, Saye ^a   Back, David J ^a   Tjia, John F ^a   Waitt, Catriona J ^a   Chaponda, Masautso ^a   Davies, Geraint ^a   Ardrey, Alison ^b   Ashleigh, Samantha ^b   Ward, Stephen A ^b  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b LIVERPOOL SCHOOL OF TROPICAL MEDICINE   (United Kingdom)

Author keywords

Cellular; HPLC MS; Plasma; Rifampicin

Indexed keywords

BACTERIA; CELLS; DISEASES; DRUG PRODUCTS; MASS SPECTROMETRY; PLASMAS; PROTEINS;

DRUG CONCENTRATIONS; MYCOBACTERIUM TUBERCULOSIS; PERIPHERAL BLOOD MONONUCLEAR CELLS (PBMC); RIFAMPICIN;

PHARMACOKINETICS;

RIFAMPICIN;

ARTICLE; CALIBRATION; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DIAGNOSTIC VALUE; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG DOSE REGIMEN; FEMALE; FREEZE THAWING; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; MASS SPECTROMETRY; MYCOBACTERIUM TUBERCULOSIS; PRIORITY JOURNAL; QUALITY CONTROL; SEPARATION TECHNIQUE; TUBERCULOSIS;

ADMINISTRATION, ORAL; ANTITUBERCULAR AGENTS; CALIBRATION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG STABILITY; FEMALE; HUMANS; LEUKOCYTES, MONONUCLEAR; MALE; MASS SPECTROMETRY; REFERENCE STANDARDS; REPRODUCIBILITY OF RESULTS; RIFAMPIN; RIFAMYCINS; SENSITIVITY AND SPECIFICITY; TUBERCULOSIS;

MYCOBACTERIUM TUBERCULOSIS;

EID: 34548509503     PISSN: 15700232     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jchromb.2007.07.005     Document Type: Article

References (20)

1. Hartkoorn R.C., Chandler B., Owen A., Ward S.A., Bertel Squire S., Back D.J., and Khoo S.H. Tuberculosis (Edinb). (2007)
2. Seifart H.I., Kruger P.B., Parkin D.P., van Jaarsveld P.P., and Donald P.R. J. Chromatogr. 619 (1993) 285
3. Khuhawar M.Y., and Rind F.M. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 766 (2002) 357
4. Calleja I., Blanco-Prieto M.J., Ruz N., Renedo M.J., and Dios-Vieitez M.C. J. Chromatogr. A 1031 (2004) 289
5. Smith P.J., van Dyk J., and Fredericks A. Int. J. Tuberc. Lung Dis. 3 (1999) S325
6. Calleri E., De Lorenzi E., Furlanetto S., Massolini G., and Caccialanza G. J. Pharm. Biomed. Anal. 29 (2002) 1089
7. Mohan B., Sharda N., and Singh S. J. Pharm. Biomed. Anal. 31 (2003) 607
8. Walubo A., Smith P., and Folb P.I. J. Chromatogr. B Biomed. Appl. 658 (1994) 391
9. Panchagnula R., Sood A., Sharda N., Kaur K., and Kaul C.L. J. Pharm. Biomed. Anal. 18 (1999) 1013
10. Korfmacher W.A., Bloom J., Churchwell M.I., Getek T.A., Hansen Jr. E.B., Holder C.L., and McManus K.T. J. Chromatogr. Sci. 31 (1993) 498
11. Gao W.Y., Cara A., Gallo R.C., and Lori F. Proc. Natl. Acad. Sci. USA 90 (1993) 8925
12. FDA, Guidance for industry. Bioanalytical method validation, available at: http://www.fda.gov/cder/guidance/4252fnl.htm (2001).
13. Peloquin C.A., Jaresko G.S., Yong C.L., Keung A.C., Bulpitt A.E., and Jelliffe R.W. Antimicrob. Agents Chemother. 41 (1997) 2670
14. Ford J., Boffito M., Wildfire A., Hill A., Back D., Khoo S., Nelson M., Moyle G., Gazzard B., and Pozniak A. Antimicrob. Agents Chemother. 48 (2004) 2388
15. Ford J., Cornforth D., Hoggard P.G., Cuthbertson Z., Meaden E.R., Williams I., Johnson M., Daniels E., Hsyu P., Back D.J., and Khoo S.H. Antivir. Ther. 9 (2004) 77
16. Hennessy M., Clarke S., Spiers J.P., Mulcahy F., Kelleher D., Meadon E., Maher B., Bergin C., Khoo S., Tjia J., Hoggard P., Back D., and Barry M. Antivir. Ther. 8 (2003) 191
17. Almond L.M., Edirisinghe D., Dalton M., Bonington A., Back D.J., and Khoo S.H. Clin. Pharmacol. Ther. 78 (2005) 132
18. In: Dollery C. (Ed). Rifampin, Therapeutic Drugs. second ed. (1998), Churchill Livingstone, Edinburgh R32
19. Acocella G., Pagani V., Marchetti M., Baroni G.C., and Nicolis F.B. Chemotherapy 16 (1971) 356
20. Forsgren A., and Bellahsene A. Scand. J. Infect. Dis. Suppl. 44 (1985) 16